Journal of Thoracic Oncology
Publisher: Elsevier · ISSN 1556-0864 · 83 articles
- Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L
- Thymic Composition Predicts Radiation Pneumonitis in Locally Advanced NSCLC
- Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma
- SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy
- Can Postoperative Pathology Guide Preoperative Segmentectomy Decisions?
- A Response to the Letter to the Editor: “Can postoperative pathology guide preoperative segmentectomy decisions?”
- Percent Thymic Tissue and Pneumonitis Risk in Locally Advanced NSCLC: From Predictive Signal to Clinical Actionability
- A Response to the Letter to the Editor: “Percent Thymic Tissue and Pneumonitis Risk in Locally Advanced NSCLC: From Predictive Signal to Clinical Actionability”
- Brief Report: Characterization of the Potentially Actionable TP53 Y220C Mutation in Non-Small Cell Lung Cancer. A Multicenter, European Thoracic Oncology Platform Study
- Erratum to ‘Response to Letter to the Editor: Implications of Clinical and Genetic Management of Subjects With BAP1 Germline Variants’ [Journal of Thoracic Oncology Volume 21 Issue 9 (2026) 103959]
- Amivantamab-Induced Capillary Leak Syndrome Successfully Treated With Intravenous Immunoglobulin Administration: Case Report
- Development and Implementation of an Integrated Early Lung Cancer Detection Program in Ethiopia: A Scalable Framework for Resource-Constrained Settings
- Brief report: Clinical and Functional Characterization of Rare Germline and Somatic EGFR Variants in Three Patients with Non-Small Cell Lung Cancer
- Editorial Board
- Board of Directors
- Meeting Announcements
- Table of Contents
- In This Issue
- Tobacco News Update - From the IASLC Tobacco Control Committee
- The Price of Progress in Lung Cancer: Global Disparities, Drug Costs, and the Challenge of Equitable Access
- The Weight of Success: Managing Visceral Adiposity in the Lorlatinib Era
- Finding Synergy Without Sacrificing Safety: Novel Combination Therapies in NSCLC
- Is Homozygous Methylthioadenosine Phosphorylase Deletion (MTAP−/−) in NSCLC an Important, Actionable, Adverse Prognostic Factor in Both Non-AGA+ and AGA+ NSCLC
- Deeper, Broader, or Smarter? The Race for the Best Minimal Residual Disease Assay Remains Wide Open
- Cytisine for Smoking Cessation in Lung Cancer Screening Participants: Promise, Caveats, and a Path Forward
- Tarlatamab in Pulmonary Carcinoid: A Signal Worth Chasing, Carefully
- Smoking and Cessation Across the Continuum of Cancer Care: 20 Years of Progress Toward Cessation as Standard Cancer Treatment
- Ending Tobacco Use Without Redistributing Tobacco Harm
- Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid
- Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial